Outcomes of Maintenance Treatment With the Poly ADP–Ribose Polymerase Inhibitor Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma
J. Clin. Oncol 2022 Aug 12;[EPub Ahead of Print], SJ Crabb, S Hussain, E Soulis, S Hinsley, L Dempsey, A Trevethan, Y Song, J Barber, J Frew, J Gale, G Faust, S Brock, U McGovern, O Parikh, D Enting, S Sundar, G Ratnayake, K Lees, AJ Birtle, T Powles, RJ JonesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.